<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00373503</url>
  </required_header>
  <id_info>
    <org_study_id>4942</org_study_id>
    <secondary_id>R01DA019239</secondary_id>
    <nct_id>NCT00373503</nct_id>
  </id_info>
  <brief_title>Effect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse</brief_title>
  <official_title>Effect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the interaction between marijuana and two&#xD;
      potential treatment medications: lofexidine and oral THC, with the direct goal of using this&#xD;
      information to improve marijuana treatment outcome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Only a small percentage of dependent-marijuana smokers who are seeking treatment for their&#xD;
      marijuana use is able to achieve sustained abstinence. The objective of this study is to&#xD;
      investigate the interaction between marijuana and two potential treatment medications:&#xD;
      lofexidine and oral THC, with the direct goal of using this information to improve marijuana&#xD;
      treatment outcome. In mice, the α2-receptor agonist, clonidine, reversed symptoms of&#xD;
      cannabinoid withdrawal (Lichtman et al., 2001). The purpose of this study is to determine if&#xD;
      lofexidine, an α2-receptor agonist with a more favorable side-effect profile than clonidine,&#xD;
      decreases symptoms of marijuana withdrawal and thus decreases marijuana relapse, as compared&#xD;
      to placebo. Oral THC is FDA-approved for appetite enhancement. Lofexidine, which is currently&#xD;
      not FDA-approved, is used in Europe to treat symptoms of heroin withdrawal, and to treat&#xD;
      hypertension. For the purposes of this model, relapse is defined to a return to marijuana use&#xD;
      after a period of abstinence. We have shown that oral THC reduces symptoms of marijuana&#xD;
      withdrawal at doses that produce minimal intoxication (Haney et al., 2004). Thus, the effects&#xD;
      of oral THC alone and in combination with lofexidine will be determined. The study will&#xD;
      utilize an inpatient/outpatient, counter-balanced design, with each participant maintained on&#xD;
      each of four medication conditions for 8 days each: placebo, lofexidine, oral THC, and oral&#xD;
      THC combined with lofexidine. During the inpatient study phases, participants will have the&#xD;
      opportunity to self-administer placebo or active marijuana 6 times per day. Outpatient phases&#xD;
      are for medication clearance so no medications will be administered. This study will provide&#xD;
      important information of the effect of these potential treatment medications on both&#xD;
      marijuana withdrawal symptoms, and on subsequent marijuana self-administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>marijuana relapse</measure>
    <time_frame>4 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>marijuana withdrawal symptoms</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>cardiovascular effects</measure>
    <time_frame>7 days</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Marijuana Dependence</condition>
  <arm_group>
    <arm_group_label>lofexidine, dronabinol, marijuana</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lofexidine (.6 mg qid), dronabinol (20 mg tid)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lofexidine</intervention_name>
    <description>alpha 2 adrenergic agonist, hypothesized to decrease noradrenergic activity</description>
    <arm_group_label>lofexidine, dronabinol, marijuana</arm_group_label>
    <other_name>Britlofex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dronabinol</intervention_name>
    <description>cannabinoid agonist hypothesized to decrease MJ withdrawal</description>
    <arm_group_label>lofexidine, dronabinol, marijuana</arm_group_label>
    <other_name>THC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Marijuana</intervention_name>
    <description>marijuana intoxication, withdrawal and relapse assessed</description>
    <arm_group_label>lofexidine, dronabinol, marijuana</arm_group_label>
    <other_name>cannabis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Current marijuana use: average of 3 marijuana cigarettes at least 4 times per week for&#xD;
             the past 4 weeks&#xD;
&#xD;
          -  Able to perform study procedures&#xD;
&#xD;
          -  21-45 years of age&#xD;
&#xD;
          -  Women practicing an effective form of birth control (condoms, diaphragm, birth control&#xD;
             pill, IUD)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current, repeated illicit drug use (other than marijuana)&#xD;
&#xD;
          -  Presence of significant medical illness (e.g., diabetes, cardiovascular disease,&#xD;
             hypertension, clinically significant laboratory abnormalities)&#xD;
&#xD;
          -  Bradycardia (55 beats/minute), hypotension (&lt; 90 mmHg) including orthostatic&#xD;
             hypotension (&gt; 20 mmHg decrease in SP, or &gt; 10 mmHg decrease in DP upon standing&#xD;
&#xD;
          -  History of heart disease&#xD;
&#xD;
          -  Request for drug treatment&#xD;
&#xD;
          -  Current parole or probation&#xD;
&#xD;
          -  Pregnancy or current lactation&#xD;
&#xD;
          -  Recent history of significant violent behavior&#xD;
&#xD;
          -  Major current Axis I psychopathology (e.g., major depressive disorder, bipolar&#xD;
             disorder,suicide risk, schizophrenia)&#xD;
&#xD;
          -  Current use of any prescription or over-the-counter medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret Haney, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>September 7, 2006</study_first_submitted>
  <study_first_submitted_qc>September 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2006</study_first_posted>
  <last_update_submitted>February 4, 2013</last_update_submitted>
  <last_update_submitted_qc>February 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lofexidine</keyword>
  <keyword>Oral THC</keyword>
  <keyword>Cannabinoids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lofexidine</mesh_term>
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

